GlobeNewsWire
15 Jul 2026, 11:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ERNA-101 in combination with anti-PD-1 therapy achieved complete tumor clearance and long-term survival in 67% of treated animals in an independent preclinical study. — Strong independent validation of a lead candidate's efficacy in a larger study significantly reduces the risk of failure and increases the probability of clinical success.
+0.80Ernexa Therapeutics plans to submit an Investigational New Drug (IND) application in Q3 2026, with Phase 1 clinical trials expected to begin in Q4 2026. — Transitioning from preclinical to clinical stage is a major value-inflection point for biotech companies.
+0.60No complete tumor clearance was observed in control groups or animals receiving ERNA-101 or anti-PD-1 as monotherapies. — Demonstrates that the synergy of the combination therapy is the specific driver of the result, strengthening the scientific case for the drug's mechanism.
+0.50Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company announced successful independent validation of its lead candidate ERNA-101, showing complete tumor clearance and durable survival in preclinical models.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
